Drugs / S095029
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05162755 | Oct 2021 → Feb 2024 | cancer | Servier | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06116136 | Aug 2024 → Aug 2027 expected | gastroesophageal junction adenocarcinoma | Servier Bio-Innovation LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06162572 | Aug 2024 → Apr 2027 expected | non-small cell lung carcinoma | Servier Bio-Innovation LLC | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S095029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06162572 ↗ |
| Action | Inhibit | “blocking the interaction with its ligand HLA-E” PMID 42103356 ↗ May 2026 |
| Modality | Monoclonal antibody | “S095029 is a fully human monoclonal IgG1 anti-NKG2A antibody” PMID 42103356 ↗ May 2026 |
| Route | Intravenous | “S095029 will be administered via IV infusion every 2 weeks.” NCT05162755 ↗ |